Open Offer Launch, Posting of Circular & GM Notice

RNS Number : 8001I

Creo Medical Group PLC

16 August 2021

 

THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

LEI: 213800H188ZDCWWXFA21

16 August 2021

Creo Medical Group plc

("Creo" or the "Company")

Launch of Open Offer, Posting of Circular

and

Notice of General Meeting

The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No: 5145I ) regarding the Fundraising (the "Launch Announcement"), i t is proposing to raise up to approximately £5.07 million (before expenses) through an Open Offer pursuant to which Qualifying Shareholders will have an opportunity to subscribe for an aggregate of 2,775,896 Open Offer Shares at an Offer Price of 182.5 pence per Open Offer Share.

Pursuant to the Open Offer, Qualifying Shareholders will be given the opportunity to subscribe for:

1  Open Offer Share for every  58  Existing Ordinary Shares

held by Qualifying Shareholders at the Record Date and so on in proportion for any other number of Existing Shares then held.

Any Open Offer Shares not subscribed for by Qualifying Shareholders will be available to Qualifying Shareholders under the Excess Application Facility  and as such, Qualifying Shareholders seeking to limit their dilution from the Placing can also request additional Open Offer Shares ("Excess Shares") under the Excess Application Facility. The Open Offer is not being underwritten. 

The Open Offer is conditional upon, among other things (i) the Resolutions being duly passed by Shareholders at the General Meeting and (ii) Admission having become effective at or before 8.00 a.m. on 7 September 2021 (or such later time and/or date as Cenkos may agree with the Company not being later than 8.00 a.m. on 14 September 2021).

Posting of Circular 

The Company also confirms that a circular, which contains further details regarding the Open Offer and a notice convening the General Meeting (the "Circular"), has been posted today to Qualifying Shareholders, along with the Application Form (where applicable).   The Circular will also be made available on the Company's website:  www.creomedical/investors .

Notice of General Meeting

The General Meeting has been convened for 6 September 2021 at 10 a.m. at the offices of Osborne Clarke LLP, 2 Temple Back East, Temple Quay, Bristol BS1 6EG.

Capitalised terms used in this announcement have the meanings given to them in the Circular unless the context provides otherwise.

Creo Medical Group plc			www.creomedical.com
Richard Rees (CFO)			[phone]
Cenkos Securities plc			[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

Expected Timetable for the Fundraising

Announcement of the Fundraising	2021 12 August
Record Date for entitlement under the Open Offer	12 August
Announcement of the results of the Placing	13 August
Publication of the Circular, Proxy Form and, to Qualifying Non-Crest Shareholders, the Application Form	16 August
Ex-entitlement date of the Open Offer	16 August
Open Offer Entitlements and Excess Open Offer Entitlements credited to stock accounts in CREST of Qualifying CREST Shareholders	17 August
Latest recommended time and date for requested withdrawal of Basic Open Offer Entitlements from CREST	4.30 p.m. on 27 August
Latest time and date for depositing Open Offer Entitlements in CREST	3.00 p.m. on 31 August
Latest time and date for splitting of Application Forms under the Open Offer	3.00 p.m. on 1 September
Latest time and date for receipt of Forms of Proxy and CREST voting instructions	10.00 a.m. on 2 September
Latest time and date for receipt of Application Forms and payment in full under the Open Offer and settlement of relevant CREST instructions (as appropriate)	11.00 a.m. on 3 September
General Meeting	10.00 a.m. on 6 September
Results of the General Meeting and the Open Offer announced	6 September
Admission of the New Ordinary Shares to trading on AIM and commencement of dealings	8.00 a.m. on 7 September
Where applicable, expected date for CREST accounts to be credited in respect of New Ordinary Shares in uncertificated form	7 September
Where applicable, expected date for despatch of definitive share certificates for New Ordinary Shares in certificated form	21 September

 

END

 

 

FURGPUUWRUPGGCQ